Technical Analysis for ACHL - Achilles Therapeutics plc

Grade Last Price % Change Price Change
F 6.01 -3.53% -0.22
ACHL closed down 3.53 percent on Tuesday, July 27, 2021, on 70 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Very Strong N/A Down Down
Historical ACHL trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
New 52 Week Low Weakness 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -3.53%
New 52 Week Low Weakness -3.53%
Wide Bands Range Expansion -3.53%
Oversold Stochastic Weakness -3.53%
MACD Bullish Signal Line Cross Bullish -6.39%
Older End-of-Day Signals for ACHL ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 1% 5 days ago
Up 2% 8 days ago
Up 1% 8 days ago
Fell Below Previous Day's Low 8 days ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various types of solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Cancer Immunotherapy Cancer Treatments Melanoma Antineoplastic Drugs Bladder Cancer Head And Neck Cancer Breakthrough Therapy Renal Cell Carcinoma Orphan Drugs Triple Negative Breast Cancer Advanced Non Small Cell Lung Cancer Head And Neck Squamous Cell Carcinoma Immuno Oncology Biopharmaceutical

Is ACHL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 18.9476
52 Week Low 5.91
Average Volume 41,088
200-Day Moving Average 0.00
50-Day Moving Average 10.38
20-Day Moving Average 7.46
10-Day Moving Average 6.49
Average True Range 0.50
ADX 58.99
+DI 4.51
-DI 37.20
Chandelier Exit (Long, 3 ATRs) 9.89
Chandelier Exit (Short, 3 ATRs) 7.42
Upper Bollinger Bands 10.08
Lower Bollinger Band 4.85
Percent B (%b) 0.22
BandWidth 70.02
MACD Line -1.29
MACD Signal Line -1.35
MACD Histogram 0.0566
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.43
Resistance 3 (R3) 6.44 6.32 6.36
Resistance 2 (R2) 6.32 6.21 6.31 6.34
Resistance 1 (R1) 6.16 6.14 6.10 6.15 6.31
Pivot Point 6.04 6.04 6.01 6.03 6.04
Support 1 (S1) 5.88 5.93 5.82 5.87 5.71
Support 2 (S2) 5.76 5.86 5.75 5.68
Support 3 (S3) 5.60 5.76 5.66
Support 4 (S4) 5.59